SCHEMBL10407220

SCHEMBL10407220

O=C(O)c1cnn2c(S)ccnc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.56
▸ ALDH1A1 P00352 3/20 0.52
▸ MAP2K1 Q02750 1/20 0.49
▸ CLK4 Q9HAZ1 1/20 0.49
▸ DYRK1B Q9Y463 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.47
▸ TLR8 Q9NR97 1/20 0.40
▸ PIM1 P11309 4/20 0.39
▸ LIMK1 P53667 2/20 0.39
▸ MAPK9 P45984 1/20 0.39
▸ DYRK1A Q13627 1/20 0.39
▸ IRAK4 Q9NWZ3 1/20 0.39
▸ CREBBP Q92793 1/20 0.39
▸ GSK3A P49840 3/20 0.38
▸ MARK2 Q7KZI7 2/20 0.38
▸ MAPK13 O15264 2/20 0.38
▸ PDPK1 O15530 1/20 0.38
▸ PRKCZ Q05513 1/20 0.38
▸ EPHA2 P29317 1/20 0.38
▸ AKT1 P31749 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10408157 0.81 KDM4E (0.57) KDM4EALDH1A1MAP2K1CLK4DYRK1B
SCHEMBL2462603 0.81 KDM4E (0.57) KDM4EALDH1A1MAP2K1CLK4DYRK1B
SCHEMBL359062 0.79 KDM4E (0.57) KDM4EALDH1A1MAP2K1CLK4DYRK1B
SCHEMBL23728533 0.77 KDM4E (0.54) KDM4EALDH1A1MAP2K1CLK4DYRK1B
SCHEMBL29961700 0.76 KDM4E (0.52) KDM4EALDH1A1MAP2K1CLK4DYRK1B
SCHEMBL23728541 0.76 HSD11B1 (0.53) KDM4EALDH1A1MAP2K1CLK4DYRK1B
SCHEMBL18208300 0.76 KDM4E (0.56) KDM4EALDH1A1MAP2K1CLK4DYRK1B
SCHEMBL23744975 0.76 KDM4E (0.52) KDM4EALDH1A1MAP2K1CLK4DYRK1B
SCHEMBL23744951 0.74 KDM4E (0.61) KDM4EALDH1A1MAP2K1CLK4DYRK1B
SCHEMBL31278235 0.72 MAP2K1 (0.63) KDM4EALDH1A1MAP2K1CLK4DYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4966900-A FOR MICROBISM THERAPY, BACTERIAL INFECTIONS SANKEI PHARMACEUTICAL COMPANY LTD. (JP) 1990-10-30 — — US disclosed
EP-0254495-A2 Beta-Lactam compound, method for preparing the same, medicinal composition for bacterially infectious disease therapy containing the same and intermediates for synthesis of the same SANKEI PHARMACEUTICAL COMPANY LIMITED (JP) 1988-01-27 — — EP disclosed
Send feedback